Care Transitions in Renal Disease Patients

Renal Disease Clinical Trial

— CT  

Official title:

Care Transitions in Renal Disease Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01842776
• Other study ID #: 20129159
• Status: Recruiting
• Phase: N/A
• First received: April 22, 2013
• Last updated: April 25, 2013
• Start date: March 2013
• Est. completion date: December 2014

Study information

• Verified date: April 2013
• Source: Fresenius Medical Care North America
• Contact: Rebecca L Wingard, RN, MSN
• Phone: 615-567-4846
• Email: rebecca.wingard[@]fmc-na.com
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The goal of this pilot is to reduce the 30-day hospital readmission rate for dialysis patients. It is a quality improvement project that consistent of 4 "tracks." Tracks 1 & 2: Implement use of checklists of activities for staff to complete when patients are admitted to the hospital, and post-hospitalization with emphasis on fluid assessment, nutrition management, patient coaching, and communication between institutions. Track 3: Work with physicians to develop process to individualize post-hospitalization dialysis orders and improve medication reconciliation. Track 4: Use a renal Care Transitions Case Manager to follow patients in the hospital and 30 days post-hospitalization to facilitate care and patient coaching.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3300
• Est. completion date: December 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Chronic hemodialysis patients

• All patients admitted to the hospital during the study period

Exclusion Criteria:

• Patients <18 years old

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Kidney Diseases
• Renal Disease

Locations

Country	Name	City	State
United States	Fresenius	Franklin	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Fresenius Medical Care North America	Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	30-day readmission rate	Number of hospitalizations that occur within 30 days after discharge from an initial index hospitalization (convert to percentage of 30-day readmissions).	Participants will be followed for the duration of each hospital stay and 30 days post-hospitalization, for an expected average of 37 days.	No